If you have been reading about hGH fragment and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-07-31. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
In pharmacology, an inverse agonist is a drug that binds to the same receptor as an agonist but induces a pharmacological response opposite to that of the agonist. A neutral antagonist has no activity in the absence of an agonist or inverse agonist but can block the activity of either; they are in fact sometimes called blockers (examples include alpha blockers, beta blockers, and calcium channel blockers). Inverse agonists have opposite actions to those of agonists but the effects of both of these can be blocked by antagonists. A prerequisite for an inverse agonist response is that the receptor must have a constitutive (also known as intrinsic or basal) level of activity in the absence of any ligand. An agonist increases the activity of a receptor above its basal level, whereas an inverse agonist decreases the activity below the basal level. The efficacy of a full agonist is by definition 100%, a neutral antagonist has 0% efficacy, and an inverse agonist has < 0% (i.e., negative) efficacy.
This suggests that the increase in IGF-1 may not be specific to cow's milk, and may be caused by protein, minerals, or some other factors in milk unrelated to rBGH. There have been no direct comparisons of IGF-1 levels in people who drink ordinary cow's milk vs. milk stimulated by rBST. At this time, it is not clear that drinking milk, produced with or without rBST treatment, increases blood IGF-1 levels into a range that might be of concern regarding cancer risk or other health effects. IGF-1 concentrations are slightly higher (to variable degrees, depending on the study) in milk from cows treated with rBST than in untreated milk. This variability is presumed to be much less than the normal range of variation of IGF-1 in cow's milk due to natural factors, but more research is needed." As of 2014, evidence does not link rBST-treated milk with adverse health outcomes for children. Several studies have looked at the relationship between type 1 diabetes mellitus and infant feeding. Environmental triggers that may elicit an autoimmune reaction is the mechanism in which is being studied. Some studies have shown early exposure to bovine milk may predispose an infant to type 1 diabetes, whereas other studies show no causality. The American Society of Animal Science published an article in 2014 after reviewing health issues arising from the rBST debate. The article indicated "there are no new human health issues related to the use of rBST by the dairy industry. Use of rBST has no effect on the micro- and macrocomposition of milk.
Towards the end of its existence, the Bophuthatswana Defence Force (BDF) had an estimated number of 4,000 troops, mostly infantry. It was organized into six military regions, and its ground forces included two infantry battalions, possessing two armoured personnel carriers. The Bophuthatswana Air Force of 150 personnel possessed three combat aircraft and two armed helicopters. The president was commander-in-chief and was authorised to deploy the armed forces in both cross-border operations as well as domestically. During its last days in 1994, the Bophuthatswana Police had 6,002 police officers, operating from 56 police stations throughout the territory. With the dissolution of Bophuthatswana in 1994, the BDF and the Bophuthatswana Police were incorporated into the South African National Defence Force and the South African Police Service, respectively.
== Clinical significance == There is a rare pathology known as edema of Wharton’s jelly. Its causes have not been established. In some cases, the development of edema is associated with fetal hydrops. In addition, edema may occur in cases of umbilical cord hemangiomas. In such cases, the risk of compression of the umbilical cord vessels increases, which may lead to impaired blood supply to the fetus. Wharton’s jelly edema is usually detected in the second half of pregnancy. The edema may involve the entire umbilical cord or only certain segments of it. In addition to edema, pathologies of Wharton’s jelly include mucoid degeneration accompanied by the formation of pseudocysts, as well as underdevelopment and constriction (coarctation) of the umbilical cord. A 2015 study showed that transplantation of Wharton’s jelly tissue may be considered as a strategy for the treatment of traumatic brain injury.
==== Misconceptions about sickle cell disease ==== The stigma around the disease is particularly bad in regions of the country that are not as affected. For example, Eastern Ugandans tend to be more knowledgeable of the disease than Western Ugandans, who are more likely to believe that sickle cell disease resulted as a punishment from God or witchcraft. Other misconceptions about sickle cell disease include the belief that it is caused by environmental factors but, in reality, sickle cell disease is a genetic disease. There have been efforts throughout Uganda to address the social misconceptions about the disease. In 2013, the Uganda Sickle Cell Rescue Foundation was established to spread awareness of sickle cell disease and combat the social stigma attached to the disease. In addition to this organisation's efforts, there is a need for the inclusion of sickle cell disease education in preexisting community health education programmes to reduce the stigmatisation of sickle cell disease in Uganda.
Sources: en.wikipedia.org
== Conservative and radical replacements == Not all amino acid replacements have the same effect on function or structure of protein. The magnitude of this process may vary depending on how similar or dissimilar the replaced amino acids are, as well as on their position in the sequence or the structure. Similarity between amino acids can be calculated based on substitution matrices, physico-chemical distance, or simple properties such as amino acid size or charge (see also amino acid chemical properties). Usually amino acids are thus classified into two types:
Since the war, the US has had a continued presence of 5,000 troops stationed in Saudi Arabia – a figure that rose to 10,000 during the 2003 conflict in Iraq. Operation Southern Watch enforced the no-fly zones over southern Iraq set up after 1991; oil exports through the Persian Gulf's shipping lanes were protected by the Bahrain-based US Fifth Fleet. Since Saudi Arabia houses Mecca and Medina, Islam's holiest sites, many Muslims were upset at the permanent military presence. The continued presence of U.S. troops in Saudi Arabia after the war was one of the stated motivations behind the 11 September terrorist attacks, the Khobar Towers bombing, and the date chosen for the 1998 US embassy bombings (7 August), which was eight years to the day that US troops were sent to Saudi Arabia. Osama bin Laden interpreted the Islamic prophet Muhammad as banning the "permanent presence of infidels in Arabia". In 1996, bin Laden issued a fatwa, calling for US troops to leave Saudi Arabia. In a December 1999 interview with Rahimullah Yusufzai, bin Laden said he felt that Americans were "too near to Mecca" and considered this a provocation to the entire Islamic world.
=== Fl–Fu === Louis B. Flexner (1902–1996). American biochemist at the University of Pennsylvania, who worked on the biochemistry of memory and brain function. Member Natl. Acad. Sci. USA. Otto Folin (1867–1934). Swedish-American chemist at Harvard, best known for developing methods for the determination of the constituents of protein-free blood filtrates. Member Natl. Acad. Sci. USA. Karl August Folkers (1906–1997). American biochemist at Merck, known for work on the antibiotics cathomycin and cycloserine. Ivar Asbjørn Følling (1888–1973). Norwegian biochemist and geneticist who first described phenylketonuria. Sidney W. Fox (1912–1998). American biochemist at the University of Miami who worked on the production of amino acids in abiotic conditions. Heinz Fraenkel-Conrat (1910–1999). German-American biochemist at UC Berkeley, known for research on viruses such as tobacco mosaic virus. Member Natl. Acad. Sci. USA. Rosalind Franklin (1920–1958). British X-ray crystallographer at King's and Birkbeck Colleges, London, who worked on the structure of DNA Perry A. Frey (b. 1935). American biochemist at the University of Wisconsin known for work on enzyme mechanisms. Member Natl. Acad. Sci. USA. Irwin Fridovich (1929–2019). American biochemist at Duke University, who discovered superoxide dismutase and studied its mechanisms and superoxide toxicity. Member Natl. Acad. Sci. USA. Joseph S. Fruton (1912–2007). Polish-American biochemist at the Rockefeller Institute.
It is often found growing amid normally colored death caps. It has been described, in 2004, as a distinct variety and includes what was termed A. verna var. tarda. The true A. verna fruits in spring and turns yellow with KOH solution, whereas A. phalloides never does.
There, Freeman encounters dead scientists who teleported to Xen before him. He kills a large alien, the Gonarch, and finds a factory that manufactures alien soldiers. Finally, he enters the Nihilanth's lair and kills it. Freeman is detained by the G-Man, a mysterious agent who claims his "employers" wish to hire Freeman. If he accepts, Freeman is placed into stasis; if not, he is teleported to his death.
Sources: en.wikipedia.org
The first physical sign of puberty in females is usually a firm, tender lump under the center of the areola of one or both breasts, occurring on average at about 10½ years of age. This is referred to as thelarche. By the widely used Tanner staging of puberty, this is stage 2 of breast development (stage 1 is a flat, prepubertal breast). Within 6–12 months, the swelling has clearly begun in both sides, softened, and can be felt and seen extending beyond the edges of the areolae. This is stage 3 of breast development. By another 12 months (stage 4), the breasts are approaching mature size and shape, with areolae and nipples forming a secondary mound. In most young women, this mound disappears into the contour of the mature breast (stage 5), although there is so much variation in sizes and shapes of adult breasts that stages 4 and 5 are not always separately identifiable.
==== Themed channels ==== Besides broadcasting on the main three public television channels, The NOS is also responsible for NPO Politiek en Nieuws, a television channel that was a result of the merger of NPO Nieuws and NPO Politiek in 2021, that airs news programs, including the latest NOS Journaal as well as covering live events, parliamentary sessions, debate and archive material of parliamentary sessions. When parliament was not in session, NPO Sport took its place where it featured live sports coverage or news and current affairs being programmed which were also supplied by the NOS.
The molecules that contribute vitamin E activity are four tocopherols and four tocotrienols, within each group of four identified by the prefixes alpha- (α-), beta- (β-), gamma- (γ-), and delta- (δ-). For alpha(α)-tocopherol each of the three "R" sites has a methyl group (CH3) attached. For beta(β)-tocopherol: R1 = methyl group, R2 = H, R3 = methyl group. For gamma(γ)-tocopherol: R1 = H, R2 = methyl group, R3 = methyl group. For delta(δ)-tocopherol: R1 = H, R2 = H, R3 = methyl group. The same configurations exist for the tocotrienols, except that the unsaturated side chain has three carbon-carbon double bonds whereas the tocopherols have a saturated side chain. (Esters such as alpha-tocopherol acetate are digested in the human body to yield the corresponding tocopherol.) Nutritional labeling only takes into account the α-tocopherol form because the human liver preferentially retains this form due to the structure of alpha-tocopherol transfer protein. This form is present in much higher amounts in blood plasma than other forms, and it is known to cover the dietary requirement of vitamin E. The other forms are not considered essential.
== Sports == Canberra Raiders, Australian rugby league football club Chitwan Rhinos, a professional Twenty20 cricket franchise representing Chitwan District, Nepal in the Nepal Premier League (NPL) Colorado Rockies, a Major League Baseball team Cincinnati Reds, another Major League Baseball team Colorado Rockies (NHL), a former National Hockey League team Cristiano Ronaldo, Portuguese footballer Commonwealth record in athletics Commonwealth record in swimming
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.